Kincell Bio Expands Production With New Manufacturing Partner at its Gainesville, FL Facility

Audio By Carbonatix

GAINESVILLE, Fla.--(BUSINESS WIRE)--Sep 16, 2024--

Kincell Bio, a cell therapy-focused cGMP contract development and manufacturing organization (CDMO), today announced that it has welcomed a new client for the production of a cell therapy product to address degenerative disease.

The agreement represents a multi-year partnership to produce patient-specific batches of clinical-grade product at its site in Gainesville, Florida. The multi-year contract adds to the work for other clients already in progress at the site.

“We’re delighted to welcome another client to our Gainesville facility,” said Bruce Thompson, PhD., CEO of Kincell Bio. “Our facility is GMP-ready, and our team thrives on providing critical CMC development and manufacturing expertise to support our clients’ clinical development plans to help patients.”

The client is a clinical stage cell therapy company pursuing regenerative medicine in a variety of critical indications. This project reflects Kincell Bio’s expanding portfolio, reinforcing its position as a strong partner in the cell therapy CDMO space.

About Kincell Bio

Kincell Bio engineers cells into therapies. A technology-forward contract development and manufacturing organization (CDMO), Kincell has facilities in both Gainesville, FL and Durham, NC. Kincell was formed to streamline analytical development, process development, CMC consulting and early-stage through registrational GMP cell therapy manufacturing. For more information, visit www.kincellbio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20240916059649/en/

CONTACT: Business & Media Enquiries

Bruce Thompson, PhD

Chief Executive Officer

[email protected]

KEYWORD: FLORIDA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: MANAGED CARE GENERAL HEALTH INFECTIOUS DISEASES HOSPITALS SCIENCE GENETICS CLINICAL TRIALS CARDIOLOGY BIOTECHNOLOGY HEALTH CHEMICALS/PLASTICS RESEARCH MANUFACTURING PHARMACEUTICAL STEM CELLS PRACTICE MANAGEMENT ONCOLOGY

SOURCE: Kincell Bio

Copyright Business Wire 2024.

PUB: 09/16/2024 07:00 AM/DISC: 09/16/2024 07:00 AM

http://www.businesswire.com/news/home/20240916059649/en